Peptide therapies are short chains of amino acids, smaller than full proteins, administered for various claimed purposes including tissue repair, growth hormone stimulation, and general anti-aging effects, a broad, loosely defined corner of the longevity market encompassing dozens of distinct compounds rather than one specific, uniform, well-vetted intervention. Worth understanding this breadth and the genuine regulatory gap around most of these compounds before assuming the category as a whole carries any particular evidence standard.
- A broad category encompassing dozens of distinct compounds, not one uniform intervention.
- Most popular peptides lack FDA approval for their commonly claimed uses.
- Sourced through compounding pharmacies or research-chemical channels with minimal oversight.
- Purity, dosing accuracy, and contamination are genuine, practical, separate concerns.
The genuine regulatory gap
Most peptides popularly discussed in longevity and performance circles, including commonly mentioned compounds like BPC-157, lack FDA approval for the specific purposes they're being used for, and lack the robust, large-scale human clinical trial evidence that would typically accompany an approved medication. They're generally sourced through compounding pharmacies, which operate under a different, less stringent regulatory framework than approved pharmaceutical manufacturing, or in some cases through research-chemical channels intended for laboratory use rather than human consumption, with correspondingly minimal quality oversight.
The practical risks, which are separate from whether it works
These are specific, not general. Compounds come from suppliers with no quality control, so there is no assurance of what is in the vial. Administration is injectable and usually unsupervised. And there is no adverse-event reporting pathway, so nothing that goes wrong is recorded anywhere.
Separate from the open question of whether any given peptide is actually effective for its claimed purpose, product purity, accurate dosing, and contamination are genuine, practical concerns given how limited regulatory oversight is throughout much of this supply chain, a product sold as a specific peptide at a specific concentration may not reliably contain what the label claims, a risk category distinct from, and arguably more immediately concerning than, the underlying efficacy question itself.
What peptides are, and why the category is so confusing
Peptide is a structural description, not a therapeutic class. That single fact explains most of the confusion, and a good deal of the marketing.
The definition
A peptide is a short chain of amino acids, conventionally under about 50, linked by peptide bonds. Longer chains are proteins. That is the entire distinction — it says nothing about what the molecule does, how well it is evidenced, or whether it is legal.
Because the category is defined by size, it contains both insulin and unregulated research chemicals, which is how a marketing claim like "peptides are used in medicine" can be technically true and completely uninformative.
Approved peptide medicines
- Insulin. In clinical use for a century.
- GLP-1 receptor agonists. Semaglutide and relatives, covered in GLP-1 medications.
- Teriparatide. A parathyroid hormone fragment approved for osteoporosis.
- Octreotide, leuprolide, desmopressin and others, each approved for defined conditions with trial evidence.
The unapproved market
The compounds sold in longevity and fitness circles are a different set. BPC-157 is a synthetic fragment promoted for tissue healing on the basis of rodent studies, with essentially no human trial evidence. Growth hormone secretagogues such as ipamorelin and CJC-1295 aim to stimulate endogenous growth hormone release. Thymosin beta-4 and epitalon are marketed on similarly thin bases.
These are typically sold labeled "for research use only, not for human consumption" — a formulation that exists to sidestep regulation rather than to describe intent.
The practical risks, ranked
The efficacy question is the one buyers focus on, and it is the less immediate risk. Products from unregulated suppliers carry no guarantee of identity, purity, dose accuracy or sterility. Injectable products manufactured without sterile controls carry infection risk that has nothing to do with whether the compound works.
There is also a route-of-administration problem worth understanding: peptides are digested like any other protein, so oral peptide products generally can’t deliver an intact molecule. Most legitimate peptide drugs are injected for exactly this reason.
Anyone in tested sport should assume prohibition. Many of these compounds appear on the World Anti-Doping Agency list, including several marketed purely for recovery.
The main peptides, and what evidence exists for each
No study is cited for any compound in this section. The two sources on this page cover regulatory and sporting status, not efficacy. Where a description below reports an effect, treat it as an account of what is claimed for the compound rather than of what has been demonstrated in people, and check each compound individually before acting on it.
Below are the compounds that come up most often in longevity and performance discussion. The evidence column describes what has been published, not what is claimed by sellers. Approval status is included separately because the two frequently diverge, and it is the single fastest way to gauge how much scrutiny a compound has actually faced.
One pattern is worth noticing before reading the table. The compounds with real human trial evidence behind them are approved medicines with narrow indications. The compounds marketed for general longevity are, almost without exception, the ones with animal data or none.
| Peptide | Claimed use | Published evidence | Status |
|---|---|---|---|
| BPC-157 Body Protection Compound | Tissue repair, tendon and gut healing | Rodent studies only. No published human trials. | Not approved anywhere. Banned by WADA. |
| TB-500 / Thymosin β4 Synthetic thymosin fragment | Tissue repair, injury recovery | Animal work on wound healing. No human efficacy trials. | Not approved. Banned by WADA. |
| CJC-1295 GHRH analogue | Raises growth hormone and IGF-1 | Small human pharmacokinetic studies show GH rises. No outcome trials. | Not approved. Banned by WADA. |
| Ipamorelin Ghrelin receptor agonist | Raises growth hormone, appetite | Early-phase human studies for post-operative ileus, discontinued. None for aging. | Not approved. Banned by WADA. |
| Sermorelin GHRH analogue | Raises growth hormone | Was FDA-approved for pediatric GH deficiency. Withdrawn from the US market in 2008 for commercial reasons. | Compounded only. Banned by WADA. |
| Tesamorelin GHRH analogue | Reduces visceral fat | FDA-approved for HIV-associated lipodystrophy, with real trial evidence in that population. | Approved, narrow indication. Banned by WADA. |
| Epitalon Synthetic pineal tetrapeptide | Telomerase activation, lifespan | Russian studies from the 1980s onward. Not independently replicated to Western standards. | Not approved. |
| GHK-Cu Copper-binding tripeptide | Skin repair, collagen | Genuine in vitro and topical skin research. Injectable systemic use is unstudied. | Topical cosmetic use is common and unregulated as a drug. |
| MOTS-c Mitochondrial-derived peptide | Metabolic regulation, exercise mimetic | Mouse metabolic studies. Human data essentially absent. | Not approved. Banned by WADA. |
| Semaglutide / Tirzepatide GLP-1 and GIP/GLP-1 agonists | Weight loss, glycemic control | Large phase 3 trials, including cardiovascular outcome data. | FDA-approved. The strongest evidence in this table by a wide margin. |
Approved peptide medications against the broader unapproved category. The same word covers both.
Two entries in that table are doing something different from the rest. Tesamorelin and the GLP-1 agonists went through full trials for defined conditions and are prescribed accordingly. Their presence in a peptide list is a fact about molecular structure rather than evidence that the category as a whole works.
Nothing here is a recommendation. It is a reference for reading a claim you encounter elsewhere, and the most useful column is usually the one showing what hasn’t been studied.
Approved medications vs. this broader category
| FDA-Approved Medications | Most Popular Peptide Therapies | |
|---|---|---|
| Regulatory approval | Yes, for specific indications | Generally no, for the claimed longevity/performance uses |
| Human trial evidence | Robust, required for approval | Often limited or absent |
| Manufacturing oversight | Strict, standardized | Variable, compounding pharmacy or research-chemical channels |
Approved peptide medications against the broader unapproved category. The same word covers both.
Checking one compound at a time
Consumer health content bundles peptide therapies together with FDA-approved medications, which blurs a real regulatory and evidence distinction. The GLP-1 medications are peptides that are approved, prescribed for defined indications and backed by outcome trials. A vial ordered from a website is the same word describing something else entirely, and the growth hormone entry covers a related area where the same conflation occurs.
This isn’t one category with one answer. If you are considering a specific peptide, research that particular compound’s regulatory status and its own evidence, rather than the category’s general reputation.
Quality control is the other gap. Much of what is sold in this space isn’t made to pharmaceutical standard, and what is on the label isn’t always what is in the vial.
The app is honest about the regulatory gap here, not treated as uniformly vetted.
Sources
Key references for the claims on this page. Where a figure is attributed to a specific study or body, it is named here.
- US Food and Drug Administration. Guidance on compounded drug products and bulk drug substances, covering the regulatory status of peptides marketed outside approval. The specific guidance document is not identified here. FDA compounding
- World Anti-Doping Agency. Prohibited List, 2025 edition, section S2, covering peptide hormones and growth factors. The list is revised annually. Prohibited List
Frequently asked
Are there peptides that increase longevity?
None with human evidence for extending lifespan. Peptides marketed for longevity typically rest on animal data or on mechanism alone, and many are sold as research chemicals outside any regulatory approval. Approved peptide medicines exist, but they treat defined conditions rather than aging.
What are peptide therapies?
Short amino acid chains used for various claimed purposes, a broad category, not one uniform intervention.
Are most peptides FDA-approved?
No, most popular peptides lack approval for their commonly claimed longevity/performance uses.
What are the practical risks?
Purity, dosing accuracy, and contamination given limited regulatory oversight.
Are peptides legal to buy?
Many are sold labeled as research chemicals not for human consumption, which is a legal formulation rather than a safety assurance. That labelling exists precisely because they haven’t been approved for the use buyers intend.
What is BPC-157?
One of the most widely marketed peptides, promoted for tissue healing. The supporting evidence is animal work. It isn’t an approved human medication, and the gap between the marketing and the evidence is unusually wide even for this category.
Are peptides safe?
The efficacy question is separate from the sourcing question, and the sourcing question is the more immediate one. Products from unregulated suppliers carry real risks around purity, dosing accuracy and sterility, none of which are visible on the label.
Do peptides show up on drug tests?
Many appear on the World Anti-Doping Agency prohibited list, including several commonly marketed for recovery. Anyone in tested sport should assume a peptide is prohibited until they have confirmed otherwise.
Which peptides are actually approved medicines?
Plenty, including insulin and the GLP-1 medications. That is the source of the confusion: peptide describes a molecular structure, so approved drugs and unregulated research chemicals can both accurately be called peptides.